Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
AEZS's Cash to Debt is ranked higher than
98% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. AEZS: No Debt )
AEZS' s 10-Year Cash to Debt Range
Min: 0.44   Max: No Debt
Current: No Debt

F-Score: 4
Z-Score: -6.93
M-Score: -5.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -213526.73
AEZS's Operating margin (%) is ranked lower than
52% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. AEZS: -213526.73 )
AEZS' s 10-Year Operating margin (%) Range
Min: -1448.42   Max: -8.58
Current: -213526.73

-1448.42
-8.58
Net-margin (%) -179395.29
AEZS's Net-margin (%) is ranked lower than
52% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. AEZS: -179395.29 )
AEZS' s 10-Year Net-margin (%) Range
Min: -994.25   Max: 110.36
Current: -179395.29

-994.25
110.36
ROE (%) -213.49
AEZS's ROE (%) is ranked higher than
53% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. AEZS: -213.49 )
AEZS' s 10-Year ROE (%) Range
Min: -702.59   Max: 125.82
Current: -213.49

-702.59
125.82
ROA (%) -52.05
AEZS's ROA (%) is ranked higher than
63% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. AEZS: -52.05 )
AEZS' s 10-Year ROA (%) Range
Min: -57.39   Max: 11.16
Current: -52.05

-57.39
11.16
ROC (Joel Greenblatt) (%) -2080.16
AEZS's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. AEZS: -2080.16 )
AEZS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1640.75   Max: -15.97
Current: -2080.16

-1640.75
-15.97
Revenue Growth (%) -53.70
AEZS's Revenue Growth (%) is ranked higher than
59% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. AEZS: -53.70 )
AEZS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 131.5
Current: -53.7

0
131.5
EBITDA Growth (%) -19.60
AEZS's EBITDA Growth (%) is ranked higher than
65% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. AEZS: -19.60 )
AEZS' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 184.7
Current: -19.6

0
184.7
EPS Growth (%) -24.50
AEZS's EPS Growth (%) is ranked higher than
66% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. AEZS: -24.50 )
AEZS' s 10-Year EPS Growth (%) Range
Min: 0   Max: 65.1
Current: -24.5

0
65.1
» AEZS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

AEZS Guru Trades in Q4 2013

Jim Simons 896,445 sh (+101.79%)
Murray Stahl Sold Out
» More
Q1 2014

AEZS Guru Trades in Q1 2014

Jim Simons 44,150 sh (-95.07%)
» More
Q2 2014

AEZS Guru Trades in Q2 2014

Jim Simons 641,917 sh (+1353.95%)
» More
Q3 2014

AEZS Guru Trades in Q3 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AEZS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.20
AEZS's P/B is ranked higher than
76% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. AEZS: 5.20 )
AEZS' s 10-Year P/B Range
Min: 0.63   Max: 43.4
Current: 5.2

0.63
43.4
EV-to-EBIT -0.03
AEZS's EV-to-EBIT is ranked higher than
100% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AEZS: -0.03 )
AEZS' s 10-Year EV-to-EBIT Range
Min: -1092.9   Max: 24
Current: -0.03

-1092.9
24
Current Ratio 0.92
AEZS's Current Ratio is ranked higher than
51% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. AEZS: 0.92 )
AEZS' s 10-Year Current Ratio Range
Min: 0.92   Max: 50.67
Current: 0.92

0.92
50.67
Quick Ratio 0.92
AEZS's Quick Ratio is ranked higher than
52% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. AEZS: 0.92 )
AEZS' s 10-Year Quick Ratio Range
Min: 0.92   Max: 49
Current: 0.92

0.92
49

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -3388.90
AEZS's Earnings Yield (Greenblatt) is ranked higher than
100% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. AEZS: -3388.90 )
AEZS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.2   Max: 3794.2
Current: -3388.9

4.2
3794.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AEZ.Canada, ET81.Germany,
AEterna Zentaris, Inc., is incorporated on September 12, 1990 under the Canada Business Corporations Act (the CBCA) and continues to be governed by the CBCA. The Company is an oncology and endocrinology drug development company investigating treatments for various unmet medical needs. Its pipeline encompasses compounds at all stages of development from drug discovery through to marketed products. Its oncology pipeline also encompasses other earlier-stage programs, including AEZS-112, an oral anticancer agent which involves three mechanisms of action such as tubulin, topoisomerase II and angiogenesis inhibition which has completed a Phase 1 trial in advanced solid tumors and lymphoma. Additionally, several novel targeted anticancer candidates such as AEZS-120, a live recombinant oral tumor vaccine candidate, as well as PI3K/Erk inhibitors, including AEZS-129, AEZS-134 and AEZS-136, are currently in preclinical development. In endocrinology, the Company is preparing the filing of an NDA in the U.S. for the registration of AEZS-130, an oral ghrelin agonist, as a diagnostic test for adult growth hormone deficiency (AGHD). A Phase 3 trial under a SPA with the FDA has been completed in this indication. Furthermore, AEZS-130 is in a Phase 2A trial for the treatment of cancer-induced cachexia.
» More Articles for AEZS

Headlines

Articles On GuruFocus.com
Billionaires Hold Waning Biotechs 42% Off Oct 16 2013 
Can Keryx Succeed Without Partnership? Apr 24 2012 
Keryx Still Has High Potential from Zerenex Apr 12 2012 
comment on AEZS Oct 26 2011 
Opportunistic Coat-tailing Jan 05 2010 

More From Other Websites
Nasdaq stocks posting largest volume increases Dec 16 2014
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Aeterna Zentaris... Dec 16 2014
INVESTOR ALERT: Class Action Lawsuit Against Aeterna Zentaris Inc. Announced by Law Offices of... Dec 16 2014
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Aeterna Zentaris... Dec 11 2014
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the... Dec 11 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Dec 09 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in... Dec 05 2014
December 1, 2014 Aeterna Zentaris and Sinopharm A-Think Sign Master Collaboration Agreement for... Dec 01 2014
Aeterna Zentaris and Sinopharm A-Think Sign Master Collaboration Agreement for Zoptarelin... Dec 01 2014
Aeterna Zentaris and Sinopharm A-Think Sign Master Collaboration Agreement for Zoptarelin... Dec 01 2014
EQUITY ALERT: Rosen Law Firm Reminds Aeterna Zentaris, Inc. Investors of Important Deadline in Class... Nov 28 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Nov 25 2014
Robbins Arroyo LLP: Aeterna Zentaris Inc. (AEZS) Misled Shareholders According to a Recently Filed... Nov 25 2014
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000... Nov 21 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Aeterna... Nov 21 2014
SHAREHOLDER ALERT: Class Action Lawsuit Against Aeterna Zentaris Inc. Filed By Glancy Binkow &... Nov 21 2014
November 20, 2014 Aeterna Zentaris Adds Hollings Cancer Center to Multi-National Phase 3 Trial in... Nov 20 2014
Aeterna Zentaris Adds Hollings Cancer Center to Multi-National Phase 3 Trial in Endometrial Cancer Nov 20 2014
Aeterna Zentaris Adds Hollings Cancer Center to Multi-National Phase 3 Trial in Endometrial Cancer Nov 20 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Nov 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK